Indication
Chromosome 15q Duplication Syndrome
1 clinical trial
2 products
Clinical trial
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of 52 Weeks of Treatment With Basmisanil in Participants Aged 2 to 14 Years Old With Dup15q Syndrome Followed by a 2-Year Optional Open-Label ExtensionStatus: Completed, Estimated PCD: 2024-03-04
Product
PlaceboProduct
Basmisanil